Literature DB >> 14660667

Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679.

Marijn van der Neut Kolfschoten1, Richard J Dirven, Hans L Vos, Guido Tans, Jan Rosing, Rogier M Bertina.   

Abstract

Activated protein C (APC) exerts its anticoagulant activity via proteolytic degradation of the heavy chains of activated factor VIII (FVIIIa) and activated factor V (FVa). So far, three APC cleavage sites have been identified in the heavy chain of FVa: Arg-306, Arg-506, and Arg-679. To obtain more insight in the structural and functional implications of each individual cleavage, recombinant factor V (rFV) mutants were constructed in which two or three of the APC cleavage sites were mutated. After expression in COS-1 cells, rFV mutants were purified, activated with thrombin, and inactivated by APC. During this study we observed that activated rFV-GQA (rFVa-GQA), in which the arginines at positions 306, 506, and 679 were replaced by glycine, glutamine, and alanine, respectively, was still inactivated by APC. Further analysis showed that the inactivation of rFVa-GQA by APC was phospholipid-dependent and sensitive to an inhibitory monoclonal antibody against protein C. Inactivation proceeded via a rapid phase (kx1=5.4 x 10(4) M(-1) s(-1)) and a slow phase (kx2=3.2 x 10(3) M(-1) s(-1)). Analysis of the inactivation curves showed that the rapid phase yielded a reaction intermediate that retained approximately 80% of the original FVa activity, whereas the slow cleavage resulted in formation of a completely inactive reaction product. Inactivation of rFVa-GQA was accelerated by protein S, most likely via stimulation of the slow phase. Immunoblot analysis using a monoclonal antibody recognizing an epitope between Arg-306 and Arg-506 indicated that during the rapid phase of inactivation a fragment of 80 kDa was generated that resulted from cleavage at a residue very close to Arg-506. The slow phase was associated with the formation of fragments resulting from cleavage at a residue 1.5-2 kDa carboxyl-terminal to Arg-306. Our observations may explain the unexpectedly mild APC resistance associated with mutations at Arg-306 (FV HongKong and FV Cambridge) in the heavy chain of FV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660667     DOI: 10.1074/jbc.M308574200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Polymorphisms in factor V and antithrombin III gene in recurrent pregnancy loss: a case-control study in Indian population.

Authors:  Amit Sharma; Teena Bhakuni; Ravi Ranjan; Ravi Kumar; Kamal Kishor; Vineet Kumar Kamal; Manoranjan Mahapatra; Mohamad Aman Jairajpuri; Renu Saxena
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

2.  Cleavage at both Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C.

Authors:  Melissa A Barhoover; Michael Kalafatis
Journal:  Blood Coagul Fibrinolysis       Date:  2011-06       Impact factor: 1.276

3.  Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.

Authors:  Hai Po H Liang; Edward J Kerschen; Sreemanti Basu; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Raffaella Toso; Alireza R Rezaie; José A Fernández; Rodney M Camire; Wolfram Ruf; John H Griffin; Hartmut Weiler
Journal:  Blood       Date:  2015-09-04       Impact factor: 22.113

4.  Polymorphisms at activated protein C cleavage sites of factor V: Are they important in the absence of factor V Leiden?

Authors:  Ehsan Kheradmand; Shaghayegh Haghjooy-Javanmard; Leila Dehghani; Mohammad Saadatnia
Journal:  Iran J Neurol       Date:  2017-01-05

5.  ptFVa (Pseudonaja Textilis Venom-Derived Factor Va) Retains Structural Integrity Following Proteolysis by Activated Protein C.

Authors:  Mark Schreuder; Xiaosong Liu; Ka Lei Cheung; Pieter H Reitsma; Gerry A F Nicolaes; Mettine H A Bos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-06-24       Impact factor: 8.311

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.